報價延遲最少15分鐘:2025/01/21 18:45 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
49.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.43/2.43
|
|
企業價值
3.24B
|
| 資產負債 |
|
每股賬面淨值
24.13
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
1.08B
|
|
每股收益
20.59
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:45 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. |